surpass trial tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 SURPASS-2: Superior HbA1c and Weight
Pay in 4 interest-free payments of $7.04 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Oct 8 - Oct 13



















